-
Je něco špatně v tomto záznamu ?
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
AL. Nguyen, EK. Havrdova, D. Horakova, G. Izquierdo, T. Kalincik, A. van der Walt, M. Terzi, R. Alroughani, P. Duquette, M. Girard, A. Prat, C. Boz, P. Sola, D. Ferraro, A. Lugaresi, J. Lechner-Scott, M. Barnett, F. Grand'Maison, P. Grammond, C....
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- dospělí MeSH
- imunologické faktory terapeutické užití MeSH
- incidence MeSH
- kohortové studie MeSH
- komplikace těhotenství epidemiologie terapie MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- následné studie MeSH
- registrace MeSH
- relabující-remitující roztroušená skleróza epidemiologie terapie MeSH
- retrospektivní studie MeSH
- těhotenství MeSH
- výsledek těhotenství MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RRMS) may be increasing. OBJECTIVE: To retrospectively determine incidence of pregnancy, DMT exposure and pregnancy outcomes in women with RRMS. METHODS: We identified all women with RRMS aged 15-45 years in the MSBase Registry between 2005-2016. Annualised pregnancy incidence rates were calculated using Poisson regression models. DMT exposures and pregnancy outcomes were assessed. RESULTS: Of 9,098 women meeting inclusion criteria, 1,178 (13%) women recorded 1,521 pregnancies. The annualised incidence rate of pregnancy was 0.042 (95% CI 0.040, 0.045). A total of 635 (42%) reported pregnancies were conceived on DMT, increasing from 27% in 2006 to 62% in 2016. The median duration of DMT exposure during pregnancy was 30 days (IQR: 9, 50). There were a higher number of induced abortions on FDA pregnancy class C/D drugs compared with pregnancy class B and no DMT (p = 0.010); but no differences in spontaneous abortions, term or preterm births. CONCLUSIONS: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Avellino Italy
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Turkey
Box Hill Hospital Melbourne Australia
Brain and Mind Centre Sydney Australia
Centre Hospitalier de l'Universite de Montreal Montreal Canada
CISSS Chaudière Appalache Levis Canada
Cliniques Universitaires Saint Luc Brussels Belgium
CORe Department of Medicine University of Melbourne Melbourne Australia
CSSS Saint Jérôme Saint Jerome Canada
Department of Basic Medical Sciences Neuroscience and Sense Organs University of Bari Bari Italy
Department of Medicine and Surgery University of Parma Parma Italy
Department of Medicine University of Melbourne Melbourne Australia
Department of Neurology Alfred Hospital Melbourne Australia
Department of Neurology ASL3 Genovese Genova Italy
Department of Neurology Royal Melbourne Hospital Melbourne Australia
Department of Neuroscience Central Clinical School Monash University Melbourne Australia
Department of Rehabilitation M L Novarese Hospital Moncrivello Italy
Dipartimento di Scienze Biomediche e Neuromotorie Università Alma Mater Studiorum Bologna Italy
Division of Neurology Department of Medicine Amiri Hospital Kuwait City Kuwait
Flinders University and Medical Centre Adelaide Australia
Geelong Hospital Geelong Australia
Groene Hart ziekenhuis Gouda the Netherlands
Haydarpasa Numune Training and Research Hospital Istanbul Turkey
Hospital Clínico San Carlos Madrid Spain
Hospital de Galdakao Usansolo Galdakao Spain
Hospital Germans Trias i Pujol Spain
Hospital Universitario La Paz Madrid Spain
Hospital Universitario Virgen Macarena Sevilla Spain
IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy
John Hunter Hospital Newcastle Australia
KTU Medical Faculty Farabi Hospital Trabzon Turkey
Liverpool Hospital Sydney Australia
Medical Faculty 19 Mayis University Samsun Turkey
Nemocnice Jihlava Jihlava Czech Republic
Ospedale Civile Azienda Ospedaliero Universitaria Modena Italy
Royal Brisbane and Women's Hospital Brisbane Australia
Université Catholique de Louvain Louvain la Neuve Belgium
University Newcastle Newcastle Australia
University of Queensland Brisbane Australia
UOC Neurologia Azienda Sanitaria Unica Regionale Marche AV3 Macerata Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19027926
- 003
- CZ-PrNML
- 005
- 20190823104935.0
- 007
- ta
- 008
- 190813s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2019.01.003 $2 doi
- 035 __
- $a (PubMed)30623864
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Nguyen, Ai-Lan $u Department of Medicine, University of Melbourne, Melbourne, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
- 245 10
- $a Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study / $c AL. Nguyen, EK. Havrdova, D. Horakova, G. Izquierdo, T. Kalincik, A. van der Walt, M. Terzi, R. Alroughani, P. Duquette, M. Girard, A. Prat, C. Boz, P. Sola, D. Ferraro, A. Lugaresi, J. Lechner-Scott, M. Barnett, F. Grand'Maison, P. Grammond, C. Ramo-Tello, R. Turkoglu, P. McCombe, E. Pucci, M. Trojano, F. Granella, D. Spitaleri, V. Van Pesch, A. Soysal, C. Oreja-Guevara, F. Verheul, S. Vucic, S. Hodgkinson, M. Slee, R. Ampapa, J. Prevost, JLS. Menoyo, O. Skibina, C. Solaro, J. Olascoaga, C. Shaw, KG. Madsen, K. Naidoo, R. Hyde, H. Butzkueven, V. Jokubaitis, MSBase Study Group,
- 520 9_
- $a BACKGROUND: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RRMS) may be increasing. OBJECTIVE: To retrospectively determine incidence of pregnancy, DMT exposure and pregnancy outcomes in women with RRMS. METHODS: We identified all women with RRMS aged 15-45 years in the MSBase Registry between 2005-2016. Annualised pregnancy incidence rates were calculated using Poisson regression models. DMT exposures and pregnancy outcomes were assessed. RESULTS: Of 9,098 women meeting inclusion criteria, 1,178 (13%) women recorded 1,521 pregnancies. The annualised incidence rate of pregnancy was 0.042 (95% CI 0.040, 0.045). A total of 635 (42%) reported pregnancies were conceived on DMT, increasing from 27% in 2006 to 62% in 2016. The median duration of DMT exposure during pregnancy was 30 days (IQR: 9, 50). There were a higher number of induced abortions on FDA pregnancy class C/D drugs compared with pregnancy class B and no DMT (p = 0.010); but no differences in spontaneous abortions, term or preterm births. CONCLUSIONS: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x terapeutické užití $7 D007155
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a relabující-remitující roztroušená skleróza $x epidemiologie $x terapie $7 D020529
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a komplikace těhotenství $x epidemiologie $x terapie $7 D011248
- 650 _2
- $a výsledek těhotenství $7 D011256
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
- 700 1_
- $a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Sevilla, Spain.
- 700 1_
- $a Kalincik, Tomas $u CORe, Department of Medicine, University of Melbourne, Melbourne, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
- 700 1_
- $a van der Walt, Anneke $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia; Department of Neurology, Alfred Hospital, Melbourne, Australia; Department of Medicine (Royal Melbourne Hospital), University of Melbourne, Melbourne, Australia.
- 700 1_
- $a Terzi, Murat $u Medical Faculty, 19 Mayis University, Samsun, Turkey.
- 700 1_
- $a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait.
- 700 1_
- $a Duquette, Pierre $u Centre Hospitalier de l'Universite de Montreal, Montreal, Canada.
- 700 1_
- $a Girard, Marc $u Centre Hospitalier de l'Universite de Montreal, Montreal, Canada.
- 700 1_
- $a Prat, Alexandre $u Centre Hospitalier de l'Universite de Montreal, Montreal, Canada.
- 700 1_
- $a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Trabzon, Turkey.
- 700 1_
- $a Sola, Patrizia $u Ospedale Civile, Azienda Ospedaliero-Universitaria, Modena, Italy.
- 700 1_
- $a Ferraro, Diana $u Ospedale Civile, Azienda Ospedaliero-Universitaria, Modena, Italy.
- 700 1_
- $a Lugaresi, Alessandra $u Dipartimento di Scienze Biomediche e Neuromotorie, Università "Alma Mater Studiorum, Bologna, Italy; IRCCS "Istituto delle Scienze Neurologiche di Bologna", Bologna, Italy.
- 700 1_
- $a Lechner-Scott, Jeannette $u University Newcastle, Newcastle, Australia; John Hunter Hospital, Newcastle, Australia.
- 700 1_
- $a Barnett, Michael $u Brain and Mind Centre, Sydney, Australia.
- 700 1_
- $a Grand'Maison, Francois $u Neuro Rive-Sud, Quebec, Canada.
- 700 1_
- $a Grammond, Pierre $u CISSS Chaudière-Appalache, Levis, Canada.
- 700 1_
- $a Ramo-Tello, Cristina $u Hospital Germans Trias i Pujol, Spain.
- 700 1_
- $a Turkoglu, Recai $u Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
- 700 1_
- $a McCombe, Pamela $u University of Queensland, Brisbane, Australia; Royal Brisbane and Women's Hospital, Brisbane, Australia.
- 700 1_
- $a Pucci, Eugenio $u UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy.
- 700 1_
- $a Trojano, Maria $u Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.
- 700 1_
- $a Granella, Franco $u Department of Medicine and Surgery, University of Parma, Parma, Italy.
- 700 1_
- $a Spitaleri, Daniele $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.
- 700 1_
- $a Van Pesch, Vincent $u Cliniques Universitaires Saint-Luc, Brussels, Belgium; Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
- 700 1_
- $a Soysal, Aysun $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Turkey.
- 700 1_
- $a Oreja-Guevara, Celia $u Hospital Universitario La Paz, Madrid, Spain; Hospital Clínico San Carlos (IdISCC), Madrid, Spain.
- 700 1_
- $a Verheul, Freek $u Groene Hart ziekenhuis, Gouda, the Netherlands.
- 700 1_
- $a Vucic, Steve $u Westmead Hospital, Sydney, Australia.
- 700 1_
- $a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, Australia.
- 700 1_
- $a Slee, Mark $u Flinders University and Medical Centre, Adelaide, Australia.
- 700 1_
- $a Ampapa, Radek $u Nemocnice Jihlava, Jihlava, Czech Republic.
- 700 1_
- $a Prevost, Julie $u CSSS Saint-Jérôme, Saint-Jerome, Canada.
- 700 1_
- $a Menoyo, Jose Luis Sanchez $u Hospital de Galdakao-Usansolo, Galdakao, Spain.
- 700 1_
- $a Skibina, Olga $u Box Hill Hospital, Melbourne, Australia.
- 700 1_
- $a Solaro, Claudio $u Department of Neurology ASL3 Genovese, Genova, Italy; Department of Rehabilitation M.L. Novarese Hospital Moncrivello, Italy.
- 700 1_
- $a Olascoaga, Javier $u Hospital Donostia, Spain.
- 700 1_
- $a Shaw, Cameron $u Geelong Hospital, Geelong, Australia.
- 700 1_
- $a Madsen, Klaus Gregaard $u Biogen, Copenhagen, Denmark.
- 700 1_
- $a Naidoo, Kerisha $u Biogen, Sydney, Australia.
- 700 1_
- $a Hyde, Robert $u Biogen, Zug, Switzerland.
- 700 1_
- $a Butzkueven, Helmut $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia; Department of Neurology, Alfred Hospital, Melbourne, Australia; Department of Medicine (Royal Melbourne Hospital), University of Melbourne, Melbourne, Australia.
- 700 1_
- $a Jokubaitis, Vilija $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia; Department of Neurology, Alfred Hospital, Melbourne, Australia; Department of Medicine (Royal Melbourne Hospital), University of Melbourne, Melbourne, Australia. Electronic address: vilija.jokubaitis@monash.edu.
- 710 2_
- $a MSBase Study Group
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 28, č. - (2019), s. 235-243
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30623864 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823105150 $b ABA008
- 999 __
- $a ok $b bmc $g 1433075 $s 1066386
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 28 $c - $d 235-243 $e 20190103 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20190813
